Definitive Contract 75N91023C00035
Award Date
9/25/23
Potential Completion Date
6/30/25
Potential Value
$400K
Federal Agency
National Cancer Institute
Awardee
Riptide Therapeutics LLC
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Evanston, IL 60201, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI) to Riptide Bioscience, Inc., a for-profit small business. The contract, valued at $299,847.00, is for the validation and optimization of RP-185 as an adjuvant to exploit the immune response generated by radiation therapy. This contract was set aside for small businesses and was derived from the NIH/CDC SBIR Contract Solicitation PHS 2018-1, which...
This $399,987 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH), to Care Progress LLC, a small business limited liability company. The contract supports the development of cancer clinical trials recruitment and retention tools for participant engagement, as described in the original SBIR solicitation. The solicitation sought proposals for SBIR Phase I and Phase II contracts to conduct...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
The U.S. National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Celldex Therapeutics, Inc. in the amount of $199,398.00 on September 20, 2012. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a firm fixed price pricing type. The contract has an ultimate completion date of August 23, 2013. This SBIR Phase I award supports basic research and development activities at Celldex Therapeutics, a for-profit small...
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Oncotherapeutica, Inc. for the development of a "Prostate Cancer Selective Radioactive Prodrug". This $298,882 Firm Fixed Price contract was awarded on September 19, 2016 and has a completion date of November 18, 2017. The contract is designated as a Total Small Business set-aside.</p>
<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. government. The contract, valued at $1,499,398.79, was awarded to Siamab Therapeutics, Inc. to develop novel therapeutic agents that target cancer stem cells, as described in SBIR Topic 326. The contract has a period of performance through September 18, 2018 and is a Cost Plus Fixed Fee definitive contract.</p>
The U.S. National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Phase I contract to Isola Therapeutics Inc., a for-profit small business, for the project "Drug Delivery by Endoesophageal Lavage (EEL) to Treat Esophageal Cancer". The $455,000 fixed-price contract has a period of performance through March 14, 2025. This award was made under the NCI's SBIR program, which aims to stimulate technological innovation, strengthen the role of small businesses in...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Nomocan Pharmaceuticals LLC, a for-profit limited liability company, for $354,959. The contract is for the development of a therapeutic technology, device, or diagnostic technology to treat, detect, or diagnose pediatric cancers and rare cancers with survival rates below 50%. The contract has a firm fixed-price pricing type...
<p>The National Cancer Institute (NCI) awarded a $249,792 Small Business Innovation Research (SBIR) Phase I contract to Biotex, Inc. to develop "Instruments and Devices that Preserve Molecular Profiles in Tumors" under SBIR Topic 257. The contract is a firm-fixed-price definitive contract with a period of performance ending on June 30, 2010. This SBIR contract supports the NCI's research objectives related to advancing cancer diagnostics and therapeutics.</p>
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a for-profit subchapter S corporation. The $224,687.00 firm-fixed-price contract, awarded on September 19, 2016, is for the SBIR PHASE I TOPIC 352 CELL-BASED MODELS FOR PROSTATE CANCER HEALTH DISPARITY RESEARCH project, with a planned completion date of June 18, 2017. This contract was set aside for small businesses.</p>